NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
Key figures
- Insider buysLast 90 days, $226.5K in total
- 1
- Insider sellsLast 90 days, $6.59M in total
- 3
- 13F holdersQ2 2026, +26 vs. previous quarter
- 194
- 13F valueReported value at the end of Q2 2026
- $4.13B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Superinvestors holding NAMS, Q2 2026
3 superinvestors report holding NewAmsterdam Pharma Co N.V. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.4%
NewAmsterdam Pharma Co N.V.'s share of the portfolio
- Shares
- 4,203,567
- Value
- $142.5M
Maverick Capital
Lee Ainslie
1.0%
NewAmsterdam Pharma Co N.V.'s share of the portfolio
- Shares
- 3,267,802
- Value
- $110.7M
| Superinvestor | Weight | Value |
|---|---|---|
| Duquesne Family Office | 2.4% | $104.0M |
Latest insider trades
Open-market purchases and sales by NewAmsterdam Pharma Co N.V. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)4:30 PM ET | Sep 14 | 1 day | Davidson Michael H.Chief Executive Officer | PPurchase | +10.0K | $22.65 | +$226.5K | +1.3%792.9K after | |
| Sep 9, 2026 (view filing)4:30 PM ET | Sep 4 | 5 days | Smither John WDirector | SSale | −1.60K | $25.32 | −$40.5K | −15.4%8.76K after | |
| Aug 25, 2026 (view filing)4:30 PM ET | Aug 24 | 1 day | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −125.0K | $26.91 | −$3.36M | −64.3%69.3K after | 10b5-1 |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −105.0K | $30.34 | −$3.19M | −81.2%24.4K after | 3 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −40.0K | $30.20 | −$1.21M | −62.2%24.4K after | 2 lots10b5-1 |
| May 27, 2026 (view filing) | May 26 | 1 day | Kooij Louise FrederikaChief Accounting Officer | SSale | −65.0K | $35.69 | −$2.32M | −72.7%24.4K after | 10b5-1 |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Lange Louis GDirector | SSale | −44.6K | $30.42 | −$1.36M | −81.2%10.4K after | 2 lots |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Lange Louis GDirector | SSale | −28.2K | $29.41 | −$829.0K | −100.0%0 after | |
| Mar 9, 2026 (view filing) | Mar 5-9 | 4 days | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −300.0K | $30.30 | −$9.09M | −81.2%69.3K after | 3 lots10b5-1 |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Davidson Michael H.Chief Executive Officer | SSale | −443.7K | $33.25 | −$14.8M | −71.8%174.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in NewAmsterdam Pharma Co N.V. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18,088,902 | $613.0M | 13.35% | +1,145,128+6.8% | Added |
| Capital World Investors | 12,230,557 | $414.5M | 0.05% | +1,121,523+10.1% | Added |
| FMR LLC | 10,339,663 | $350.4M | 0.02% | +1,573,852+18.0% | Added |
| Ra Capital Management, L.P. | 9,550,191 | $323.7M | 2.81% | 00.0% | Unchanged |
| FCPM III Services B.V. | 8,490,353 | $287.7M | 38.34% | −708,547−7.7% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 4,264,789 | $144.5M | 1.51% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 4,203,567 | $142.5M | 0.41% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,806,566 | $129.0M | 7.67% | −3,500,000−47.9% | Reduced |
| Maverick Capital LtdSuperinvestorMaverick Capital | 3,267,802 | $110.7M | 1.00% | +1,081,400+49.5% | Added |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 3,070,146 | $104.0M | 2.39% | 00.0% | Unchanged |